SUNFISH
E561097
SUNFISH is a pivotal clinical trial program evaluating the efficacy and safety of risdiplam in patients with spinal muscular atrophy (SMA).
Statements (36)
| Predicate | Object |
|---|---|
| instanceOf |
clinical trial program
ⓘ
interventional clinical study ⓘ |
| abbreviation | SUNFISH ⓘ |
| developedBy |
PTC Therapeutics
NERFINISHED
ⓘ
Roche NERFINISHED ⓘ |
| drugClassStudied | SMN2 splicing modifier ⓘ |
| endpointType |
motor function outcomes
ⓘ
safety outcomes ⓘ |
| evaluates | risdiplam NERFINISHED ⓘ |
| geographicScope | multinational ⓘ |
| hasPart |
SUNFISH Part 1
NERFINISHED
ⓘ
SUNFISH Part 2 NERFINISHED ⓘ |
| hasPhase |
Phase 2
ⓘ
Phase 3 ⓘ |
| indicationStudied | treatment of spinal muscular atrophy ⓘ |
| interventionType | oral small-molecule therapy ⓘ |
| investigationalDrug | risdiplam ⓘ |
| mechanismOfActionStudied | SMN2 pre-mRNA splicing modification ⓘ |
| primaryObjective | evaluate efficacy of risdiplam in SMA ⓘ |
| relatedTo |
FIREFISH clinical trial
ⓘ
JEWELFISH clinical trial ⓘ RAINBOWFISH clinical trial ⓘ |
| routeOfAdministration | oral ⓘ |
| secondaryObjective | evaluate safety of risdiplam in SMA ⓘ |
| sponsor |
Genentech
NERFINISHED
ⓘ
Roche NERFINISHED ⓘ |
| sponsorCountry | Switzerland NERFINISHED ⓘ |
| studiesCondition | spinal muscular atrophy ⓘ |
| studyDesign |
double-blind
ⓘ
placebo-controlled ⓘ randomized ⓘ |
| targetsPopulation |
adult SMA patients
ⓘ
patients with spinal muscular atrophy ⓘ pediatric SMA patients ⓘ |
| therapeuticArea |
neuromuscular disease
ⓘ
rare disease ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.